CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We have now added a new section called the "Assay History List" to the "At A Gla...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
This is the first update to the original CTS communication distributed on July 6th. As previously co...